Cecropin A Evidence Guide
Evidence for Cecropin A is too preliminary to support a research protocol with confidence. This insect-derived antimicrobial peptide has no human data, no therapeutic trials, and limited relevance to human therapeutic development beyond serving as a template for synthetic antimicrobial peptide design.
Our Take
Evidence for Cecropin A is too preliminary to support a research protocol with confidence. This insect-derived antimicrobial peptide has no human data, no therapeutic trials, and limited relevance to human therapeutic development beyond serving as a template for synthetic antimicrobial peptide design.
- Evidence context
- Antimicrobial peptide scaffold research, synthetic AMP design reference
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol
Benefits and Evidence
- Gram-Negative Antibacterial Activity: Level D, mostly non-human evidence - Potent bactericidal activity against E. coli, Pseudomonas aeruginosa, Klebsiella, and other gram-negative pathogens demonstrated across numerous in vitro studies.
- Anti-Cancer Activity: Level D, mostly non-human evidence - Mader et al. (2005, Exp Cell Res) demonstrated that bovine lactoferricin (LfcinB, 25-residue derivative) selectively killed MDA-MB-435 breast cancer and neuroblastoma cells at 25-50 ug/mL while sparing normal fibroblasts, attributed to the higher anionic phosphatidylserine content of tumor membranes.
Side Effects and Warnings
- No human clinical data available
- Low mammalian cell toxicity in vitro at bactericidal concentrations
- Potential hemolytic activity at very high concentrations
- Not available for clinical or therapeutic use
- Rapidly degraded by mammalian proteases, limiting in vivo utility
- Synthetic analogs are being developed to improve stability
- No human safety data exists
Research Dosage References
- <strong>In vitro</strong> - 0.5-10 mcg/mL (MIC range) - N/A - Studied exclusively in laboratory settings. Minimum inhibitory concentrations vary by bacterial species.
Mechanism of Action
Cecropin A destroys bacteria through a sequential process: 1. Electrostatic binding: Cationic residues are attracted to the negatively charged outer leaflet of bacterial membranes (LPS in gram-negatives). 2. Alpha-helix insertion: The amphipathic alpha-helical structure inserts into the lipid bilayer, creating transient pores and disrupting membrane integrity. 3. Carpet model disruption: At higher concentrations, peptide molecules carpet the membrane surface, causing detergent-like solubilization of the lipid bilayer. 4. Selective toxicity: Preferentially targets bacterial membranes rich in phosphatidylglycerol and cardiolipin over cholesterol-containing mammalian membranes.
Legal Status
Cecropin A is a research reagent with no approved therapeutic use. It is studied as a template for antimicrobial-peptide drug design.
Primary Sources
Quick Answers
Where is the strongest evidence for Cecropin A?
Evidence for Cecropin A is too preliminary to support a research protocol with confidence. This insect-derived antimicrobial peptide has no human data, no therapeutic trials, and limited relevance to human therapeutic development beyond serving as a template for synthetic antimicrobial peptide design. Evidence context: Antimicrobial peptide scaffold research, synthetic AMP design reference.
What are the main side effects of Cecropin A?
Cecropin A side effects and warning signals include No human clinical data available, Low mammalian cell toxicity in vitro at bactericidal concentrations, Potential hemolytic activity at very high concentrations, Not available for clinical or therapeutic use, and Rapidly degraded by mammalian proteases, limiting in vivo utility.
What evidence level is Cecropin A?
Cecropin A is rated Level D; the listed research status is Early Research.